Nestlé is introducing a line of meals in the US to complement GLP-1 weight-loss medication.
The new Vital Pursuit products from Nestlé are protein-rich, high in fiber, packed with essential nutrients, and portion-aligned to meet the appetite of weight-loss medication users.
This range of 12 SKUs includes frozen meals like whole grain bowls, protein pasta, sandwich melts, and pizzas, all priced at $4.99 and below.
Nestlé is committed to expanding choices in its portfolio to align with consumer eating habits, with plans to launch more products under the Vital Pursuit line.
Steve Presley, CEO of Nestlé’s North America business, stated, “Vital Pursuit offers accessible, delicious food options that cater to the needs of consumers utilizing weight-loss medications, reflecting our anticipation of emerging trends.”
Vital Pursuit products will be available in the US in the fourth quarter of the year.
Tom Moe, president of Nestlé’s US meals division, emphasized the importance of providing diverse options to support individual health journeys and indicated plans for further product expansions.
GLP-1 medications are a group of anti-obesity drugs, with notable brands like Novo Nordisk’s Ozempic and Negovy gaining popularity.
In the US, JP Morgan research forecasts a potential increase in GLP-1 users to 30 million by 2030, urging companies to adapt to evolving market demands.
Nestlé is innovating to address the impact of GLP-1 drugs on consumer behavior and nutritional needs, focusing on companion products to support patients during and after therapy.
